person
Nicola F.
- Country
- Italy
- Department
- Oncologia Medica Gastrointestinale e Tumori Neuroendocrini
Research Overview
assignment
13
Clinical Trials ·
- Phase III Trial of BI 764532 Plus Carboplatin and Etoposide Versus Carboplatin and Etoposide in Previously Untreated DLL3-Positive Advanced Extrapulmonary Neuroendocrine Carcinoma
- Phase III Randomized Trial of AZD0901 with Capecitabine ± Rilvegostomig in First‑Line Claudin‑18.2‑Positive HER2‑Negative Advanced Gastric, GEJ or Esophageal Adenocarcinoma
- Phase II Dose Selection Study of Intravenous BI 764532 in Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer and Neuroendocrine Carcinomas
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
95
Sites with multiple studies
Has run more than one trial at 95 of 262 partner sites.
Specializations
Pancreatic Cancer Research
Specializes in investigating novel treatments for metastatic pancreatic adenocarcinoma, with particular focus on targeted therapies involving CLDN18.2-positive tumors.
- First-line treatment strategies
- RAS G-12 mutations
- Advanced pancreatic cancer therapeutics
Gastrointestinal Oncology
Focuses on advanced treatments for gastroenteropancreatic neuroendocrine tumors and cholangiocarcinoma, including studies of targeted therapies and novel drug combinations.
- FGFR-altered tumors
- Neuroendocrine cancer therapy
- Gastroesophageal junction adenocarcinoma
Thoracic and Neuroendocrine Oncology
Explores therapeutic approaches for small cell lung cancer and various types of neuroendocrine carcinomas, including novel treatment combinations and targeted therapies.
- Advanced thoracic NETs
- Large cell neuroendocrine carcinoma
- Somatostatin receptor-positive tumors
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.